Tinea Pedis Treatment Market by Disease Indication, Route of Administration, Distribution Channel, Drug Class & Region - Forecast 2022 – 2032
Will Providing Cost-Effective Anti-Fungal Drugs in Hospital Pharmacies Generate Maximum Profits for Tinea Pedis Drug Manufacturers? Explore FMI's Latest Study to Know More!
[286 Pages Report] The global tinea pedis treatment market is expected to reach US$ 1.35 Billion in 2022, and further expand at a CAGR rate of 5.2% to surpass US$ 2.24 Billion by the end of 2032. In terms of disease indication, the interdigital tinea pedis treatment market is expected to lead with a share of about 68.3% in 2022.
Attributes
Key Insights
Tinea Pedis Treatment Market Value 2021
US$ 1.29 Billion
Estimated Market Value 2022
US$ 1.35 Billion
Projected Market Value 2032
US$ 2.24 Billion
CAGR 2022-2032
5.2%
Market Share of Top 5 Countries
62.1%
One of the most common types of tinea infection is tinea pedis, alternatively called athlete foot. The main causative agents of tinea pedis include fungal spores found in bathrooms, swimming pools, and other wet places. Also, fewer fatty acids produced by the skin (a natural antifungal agent), wearing socks for an extended period, wearing the same pair of shoes, excessive perspiration, immunodeficiency, lymphedema, and other factors.
As per a study by NCBI in 2021, dermatophyte infections of the toe clefts may afflict 10% of the entire population. Trichophyton mentagrophytes and microsporum canis are becoming more common in China, according to a dermatology clinic study. Of the patients, 27% were found to have tinea pedis. The prevalence of tinea pedis in the U.S. is 12-18%.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Tinea Pedis Treatment Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032
As per Future Market Insights (FMI), the tinea pedis treatment market was approximately 8.9% of the overall ~US$ 14.5 Bn global anti-fungal drugs market in 2021. Sales in tinea pedis treatment market held a global market value of US$ 1.29 Bn in 2021 while growing at a CAR of nearly 4.2% from 2012 till 2021.
For the past few decades, the increased prevalence of infectious diseases across the globe due to the massive change in ecosystems and animal infections has led to the emergence of novel fungal infections. Antifungal drug prophylaxis and long-term therapeutic use in high-risk patients have facilitated the establishment of (multi) drug resistance.
In a study conducted by NCBI in the journal of ‘unicellular biology and human disease’ in June 2020, around 1.7 million people die yearly from over 150 million severe fungal infections. Tinea pedis is a very common and persistent infection in European nations. Fungal infection is found in people who participate in sports like swimming, running, and other activities.
In the U.K., tinea pedis affects 15% of people, as per the study. As a result, numerous pharma companies are investing in innovating effective antifungal drugs in the market. Increasing research and development activities is also catering to the needs of new treatment options for fungal infections and diseases.
Another study by NCBI in 2017 suggests that prevalence of tinea pedis is high in age groups of people over 60 years. Owing to the aforementioned factors, the global tinea pedis treatment market is expected to grow at a CAGR of 5.2% during the forecast period from 2022 to 2032.
What are the Key Opportunities for the Tinea Pedis Drug Manufacturers?
Rising Research Activities to Develop Anti-Fungal Drugs to Aid the Growth
As per the reports of the Indian Journal of Medical Research in 2020, the growing prevalence of fungal infections, especially in sub-tropical regions due to their temperature adaptation, causes several deaths yearly.
The market for tinea pedis drugs is set to present an opportunistic outlook, owing to the rising global awareness and advertisement of new speciality drugs for such infections. The U.S. Food and Drug Administration (FDA) is also supporting the development of such drugs.
For instance, in January 2021, the Global Anti-Microbial Resistance R&D Hub stated that 1,047 fungal R&D projects had received a total of USD 362 million in funding, most of which has gone towards human-related research studies.
The growth will further be propelled by the new adaptation of lifestyle like increased urbanization, increased usage of athletic and fitness facilities, rising obesity rates, and a rise in immunocompromised patients, providing further growth opportunities to the drug manufacturers within the tinea pedis treatment market.
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining Demand for Tinea Pedis Drugs?
Although various treatment options and antifungal drugs on the market claim improvement but there have been multiple re-occurrences of tinea pedis infection even after prolonged treatment.
Hence, the increasing concerns of the FDA and the stringent guidelines for the approval and launching of such products may pose as a deterring factor towards the growth of the market.
Another factor restraining the growth is the limited awareness of fungal infections in underdeveloped countries. These, along with patients’ non-adherence to the treatment regime, low treatment seeking rates, counterfeit and off-label drug use, high-cost constraint and lack of resources, might impede the growth in tinea pedis treatment market.
Country-wise Insights
Why is the U.S. Considered a Highly Lucrative Tinea Pedis Treatment Market?
Rising Prevalence of Skin Infections Among Millennials to Spur the Growth
The U.S. dominated the North America tinea pedis treatment market with a total share of about 96.2% in 2021 and is expected to gain traction over the forecast period. This is due to the high prevalence of skin infections, especially among teenagers. Further, rising number of product launches for the treatment will also boost the market.
What is the Outlook for China Tinea Pedis Treatment Market?
China Tinea Pedis Treatment to Gain Impetus Amid Rising Cases of Plantar Tinea Pedis
As per FMI, China is expected to account for 15.3% of the global share and is expected to witness growth at a CAGR 6.3% over the forecast period. Increasing number of patients with athlete’s foot, enhanced healthcare infrastructure and growing number of retail pharmacy chains will bolster the growth of tinea pedis treatment market.
Additionally, increasing prevalence of plantar tinea pedis, also known as moccasin foot, occurs on the side of the foot, will drive the demand in the market. Hence, several leading players are eyeing China tinea pedis treatment market to capitalize on growing need for anti-fungal drugs and serums.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Disease Indication is Driving the Tinea Pedis Treatment Market?
Nearly 7 Out of 10 Sales to Come from Interdigital Tinea Pedis
Interdigital tinea pedis, by indication, is expected to hold a market share of 68.3% in the global market in 2022 and is expected to grow at a CAGR of 5.0% during the forecast period. Interdigital tinea pedis is the most common infection (between 4th and 5th toe space). Hence, key companies are investing in research for new treatment trends and effective drugs.
Further, in terms of route of administration, the topical segment is estimated to account for 79.3% of market share globally in 2022 and is forecasted to grow at a CAGR of 5.0%. Topical form administration is considered to be the most adequate and widely used route for drug administration because of its targeted therapy and fewer side effects.
Which is the Leading Distribution Channel in the Tinea Pedis Treatment Market?
Demand to Remain High for Antifungal Drugs within Hospital Pharmacies
Hospital pharmacies will account for a market share of nearly 35% in the global market in 2022. Hospital pharmacies are expected to dominate the market as it is the most preferred location for patients for the purchase of antifungal drugs.
Meanwhile, antifungal drug class is expected to show a growth rate of 4.8% in the forecast period. Antifungals are considered the most commonly used drug class owing to their effective actions and less possibility of adverse effects.
Competitive Landscape
As per the study, the tinea pedis treatment market is highly fragmented. In order to meet the demand and expand their customer base, key companies are implementing inorganic and organic strategies such as high R&D expenses for clinical trials and new product launches.
For Instance:
In June 2022, Kerasal announced the launch of Athlete’s Foot Invisible Powder spray, Athlete’s Foot Silky Clear Gel and Athlete’s Foot Rapid Symptom Relief Medicated Soak a 5-in-1 benefit product pipeline for not only treating athlete’s foot but also improve the aesthetic appearance of skin.
On January, 2021, DermBiont an early stage bio pharmaceutical company announced positive results for their phase 2 clinical trial on their latest development DBI-001 which is a live bacterial product. It claims to show benefit towards treatment of tinea pedis and atopic dermatitis.
Report Scope as per Tinea Pedis Treatment Market Analysis
Attribute
Details
Estimated Market Value 2022
US$ 1.35 Billion
Projected Market Value 2032
US$ 2.24 Billion
CAGR 2022 to 2032
5.2%
Forecast Period
2022 to 2032
Historical Data Available for
2012 to 2021
Market Analysis
US$ Billion for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa
Key Market Segments Covered
Disease Indication , Route of Administration , Distribution Channel, Drug Class and Region
Key Market Segments Covered in Tinea Pedis Treatment Industry Research
By Disease Indication:
Interdigital Tinea Pedis
Plantar Tinea Pedis
Vesicular Tinea Pedis
By Route of Administration:
Topical
Gel
Cream
Spray
Lotion
Powder
Oral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
By Drug Class:
Antifungals
Combination
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)
Frequently Asked Questions
How much is the tinea pedis treatment market worth in 2021?
The global tinea pedis treatment market is worth US$ 1.29 Bn in 2021, and is set to expand 1.7 X over the next ten years.
What is the sales forecast for tinea pedis treatment market through 2032?
The tinea pedis treatment market is expected to reach US$ 2.24 Bn by the end of 2032, with sales revenue expected to register 5.2% CAGR.
What are the key trends shaping the tinea pedis treatment industry?
The expanding research and development in the tinea pedis treatment, rising awareness among consumers about fungal infections, immense advertising, rise in number of immunocompromised patients and rise in the geriatric population, are some of the key trends in this market.
Which are the top 5 countries driving demand for tinea pedis treatment?
U.S, China, Brazil, Japan and India are the top 5 countries and are expected to drive demand for the tinea pedis treatment industry.
What is the North American market outlook for tinea pedis treatment?
North America is one of the key markets for tinea pedis treatment, with the U.S. accounting 96.2 % of the North American tinea pedis treatment market in the year 2021.
At what percentage is the demand for tinea pedis treatment expected to register growth in Europe?
Demand for tinea pedis treatment in Europe is expected to register a growth at 5.2% CAGR over the next ten years.
Which countries are the key producers of tinea pedis treatment?
The U.S., China and Brazil are the key producers of tinea pedis treatment drugs.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Disease Indication Innovation / Development Trends
4. Key Inclusions
4.1. Key Regulations
4.2. Key Strategies Adopted by Manufacturer
4.3. PESTLE Analysis
4.4. Porter’s Analysis
4.5. Product Adoption Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Outlook
5.1.2. Global Healthcare Spending Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historical Growth of Key Players
5.2.2. Disease Indication Pipeline
5.2.3. New Product Launches
5.2.4. R&D Expenditure by Key Players
5.2.5. Rising Prevalence of Infectious Diseases
5.2.6. Adoption Rate
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-18 Crisis Analysis
6.1. COVID-18 and Impact Analysis
6.1.1. By Disease Indication
6.1.2. By Route of Administration
6.1.3. By Distribution Channel
6.1.4. By Drug Class
6.1.5. By Region
6.2. 1920 Market Scenario
7. Global Tinea Pedis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2012-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, By Disease Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis by Disease Indication, 2012-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Disease Indication, 2022-2032
8.3.1. Interdigital Tinea Pedis
8.3.2. Plantar Tinea Pedis
8.3.3. Vesicular Tinea Pedis
8.4. Market Attractiveness Analysis by Disease Indication
9. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis by Route of Administration, 2012-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032
9.3.1. Topical
9.3.1.1. Gel
9.3.1.2. Cream
9.3.1.3. Spray
9.3.1.4. Lotion
9.3.1.5. Powder
9.3.2. Oral
9.4. Market Attractiveness Analysis by Route of Administration
10. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2012-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Distribution Channel, 2022-2032
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. Online Pharmacies
10.4. Market Attractiveness Analysis by Distribution Channel
11. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Drug Class
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2012-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Class, 2022-2032
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Drug Stores
11.3.4. Online Pharmacies
11.4. Market Attractiveness Analysis by Drug Class
12. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis by Region, 2012-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
13.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Disease Indication
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.3.5. By Drug Class
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Disease Indication
13.4.3. By Route of Administration
13.4.4. By Distribution Channel
13.4.5. By Drug Class
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. U.S. Tinea Pedis Treatment Market
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Disease Indication
13.7.1.2.2. By Route of Administration
13.7.1.2.3. By Distribution Channel
13.7.1.2.4. By Drug Class
13.7.2. Canada Tinea Pedis Treatment Market
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Disease Indication
13.7.2.2.2. By Route of Administration
13.7.2.2.3. By Distribution Channel
13.7.2.2.4. By Drug Class
14. Latin America Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
14.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Disease Indication
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.3.5. By Drug Class
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Disease Indication
14.4.3. By Route of Administration
14.4.4. By Distribution Channel
14.4.5. By Drug Class
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. Brazil Tinea Pedis Treatment Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Disease Indication
14.7.1.2.2. By Route of Administration
14.7.1.2.3. By Distribution Channel
14.7.1.2.4. By Drug Class
14.7.2. Mexico Tinea Pedis Treatment Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Disease Indication
14.7.2.2.2. By Route of Administration
14.7.2.2.3. By Distribution Channel
14.7.2.2.4. By Drug Class
14.7.3. Argentina Tinea Pedis Treatment Market
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Disease Indication
14.7.3.2.2. By Route of Administration
14.7.3.2.3. By Distribution Channel
14.7.3.2.4. By Drug Class
15. Europe Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
15.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Nordic Countries
15.3.1.9. Rest of Europe
15.3.2. By Disease Indication
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.3.5. By Drug Class
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Disease Indication
15.4.3. By Route of Administration
15.4.4. By Distribution Channel
15.4.5. By Drug Class
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Germany Tinea Pedis Treatment Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Disease Indication
15.7.1.2.2. By Route of Administration
15.7.1.2.3. By Distribution Channel
15.7.1.2.4. By Drug Class
15.7.2. France Tinea Pedis Treatment Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Disease Indication
15.7.2.2.2. By Route of Administration
15.7.2.2.3. By Distribution Channel
15.7.2.2.4. By Drug Class
15.7.3. Italy Tinea Pedis Treatment Market
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Disease Indication
15.7.3.2.2. By Route of Administration
15.7.3.2.3. By Distribution Channel
15.7.3.2.4. By Drug Class
15.7.4. Spain Tinea Pedis Treatment Market
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Disease Indication
15.7.4.2.2. By Route of Administration
15.7.4.2.3. By Distribution Channel
15.7.4.2.4. By Drug Class
15.7.5. U.K. Tinea Pedis Treatment Market
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Disease Indication
15.7.5.2.2. By Route of Administration
15.7.5.2.3. By Distribution Channel
15.7.5.2.4. By Drug Class
15.7.6. BENELUX Union Tinea Pedis Treatment Market
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Disease Indication
15.7.6.2.2. By Route of Administration
15.7.6.2.3. By Distribution Channel
15.7.6.2.4. By Drug Class
15.7.7. Russia Tinea Pedis Treatment Market
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Disease Indication
15.7.7.2.2. By Route of Administration
15.7.7.2.3. By Distribution Channel
15.7.7.2.4. By Drug Class
15.7.8. Nordic Countries Tinea Pedis Treatment Market
15.7.8.1. Introduction
15.7.8.2. Market Analysis and Forecast by Market Taxonomy
15.7.8.2.1. By Disease Indication
15.7.8.2.2. By Route of Administration
15.7.8.2.3. By Distribution Channel
15.7.8.2.4. By Drug Class
16. South Asia Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
16.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Disease Indication
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.3.5. By Drug Class
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Disease Indication
16.4.3. By Route of Administration
16.4.4. By Distribution Channel
16.4.5. By Drug Class
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. India Tinea Pedis Treatment Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Disease Indication Disease Indication
16.7.1.2.2. By Route of Administration
16.7.1.2.3. By Distribution Channel
16.7.1.2.4. By Drug Class
16.7.2. Indonesia Tinea Pedis Treatment Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Disease Indication Disease Indication
16.7.2.2.2. By Route of Administration
16.7.2.2.3. By Distribution Channel
16.7.2.2.4. By Drug Class
16.7.3. Malaysia Tinea Pedis Treatment Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Disease Indication Disease Indication
16.7.3.2.2. By Route of Administration
16.7.3.2.3. By Distribution Channel
16.7.3.2.4. By Drug Class
16.7.4. Thailand Tinea Pedis Treatment Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Disease Indication Disease Indication
16.7.4.2.2. By Route of Administration
16.7.4.2.3. By Distribution Channel
16.7.4.2.4. By Drug Class
17. East Asia Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
17.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Disease Indication
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Disease Indication
17.4.3. By Route of Administration
17.4.4. By Distribution Channel
17.4.5. By Drug Class
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. China Tinea Pedis Treatment Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Disease Indication
17.7.1.2.2. By Route of Administration
17.7.1.2.3. By Distribution Channel
17.7.1.2.4. By Drug Class
17.7.2. Japan Tinea Pedis Treatment Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Disease Indication
17.7.2.2.2. By Route of Administration
17.7.2.2.3. By Distribution Channel
17.7.2.2.4. By Drug Class
17.7.3. South Korea Tinea Pedis Treatment Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Disease Indication
17.7.3.2.2. By Route of Administration
17.7.3.2.3. By Distribution Channel
17.7.3.2.4. By Drug Class
18. Oceania Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
18.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Disease Indication
18.3.3. By Route of Administration
18.3.4. By Distribution Channel
18.3.5. By Drug Class
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Disease Indication
18.4.3. By Route of Administration
18.4.4. By Distribution Channel
18.4.5. By Drug Class
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Australia Tinea Pedis Treatment Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Disease Indication
18.7.1.2.2. By Route of Administration
18.7.1.2.3. By Distribution Channel
18.7.1.2.4. By Drug Class
18.7.2. New Zealand Tinea Pedis Treatment Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Disease Indication
18.7.2.2.2. By Route of Administration
18.7.2.2.3. By Distribution Channel
18.7.2.2.4. By Drug Class
19. Middle East and Africa (MEA) Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021
19.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. Israel
19.3.1.4. North Africa
19.3.1.5. South Africa
19.3.1.6. Rest of Middle East and Africa
19.3.2. By Disease Indication
19.3.3. By Route of Administration
19.3.4. By Distribution Channel
19.3.5. By Drug Class
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Disease Indication
19.4.3. By Route of Administration
19.4.4. By Distribution Channel
19.4.5. By Drug Class
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. GCC Countries Tinea Pedis Treatment Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Disease Indication
19.7.1.2.2. By Route of Administration
19.7.1.2.3. By Distribution Channel
19.7.1.2.4. By Drug Class
19.7.2. Israel Tinea Pedis Treatment Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Disease Indication
19.7.2.2.2. By Route of Administration
19.7.2.2.3. By Distribution Channel
19.7.2.2.4. By Drug Class
19.7.3. Turkey Tinea Pedis Treatment Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Disease Indication
19.7.3.2.2. By Route of Administration
19.7.3.2.3. By Distribution Channel
19.7.3.2.4. By Drug Class
19.7.4. South Africa Tinea Pedis Treatment Market
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Disease Indication
19.7.4.2.2. By Route of Administration
19.7.4.2.3. By Distribution Channel
19.7.4.2.4. By Drug Class
19.7.5. North Africa Tinea Pedis Treatment Market
19.7.5.1. Introduction
19.7.5.2. Market Analysis and Forecast by Market Taxonomy
19.7.5.2.1. By Disease Indication
19.7.5.2.2. By Route of Administration
19.7.5.2.3. By Distribution Channel
19.7.5.2.4. By Drug Class
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Device footprint by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. STERIS
21.3.1.1. Overview & Key financials
21.3.1.2. Disease Indication Portfolio
21.3.1.3. Key Financials
21.3.1.4. Sales Footprint
21.3.1.5. Analysis Commentary
21.3.1.6. Strategy Overview
21.3.1.7. SWOT Analysis
21.3.2. Perrigo Company Plc.
21.3.2.1. Overview & Key financials
21.3.2.2. Disease Indication Portfolio
21.3.2.3. Key Financials
21.3.2.4. Sales Footprint
21.3.2.5. Analysis Commentary
21.3.2.6. Strategy Overview
21.3.2.7. SWOT Analysis
21.3.3. Novartis AG
21.3.3.1. Overview & Key financials
21.3.3.2. Disease Indication Portfolio
21.3.3.3. Key Financials
21.3.3.4. Sales Footprint
21.3.3.5. Analysis Commentary
21.3.3.6. Strategy Overview
21.3.3.7. SWOT Analysis
21.3.4. Valeant Pharmaceuticals International
21.3.4.1. Overview & Key financials
21.3.4.2. Disease Indication Portfolio
21.3.4.3. Key Financials
21.3.4.4. Sales Footprint
21.3.4.5. Analysis Commentary
21.3.4.6. Strategy Overview
21.3.4.7. SWOT Analysis
21.3.5. GlaxoSmithKline plc
21.3.5.1. Overview & Key financials
21.3.5.2. Disease Indication Portfolio
21.3.5.3. Key Financials
21.3.5.4. Sales Footprint
21.3.5.5. Analysis Commentary
21.3.5.6. Strategy Overview
21.3.5.7. SWOT Analysis
21.3.6. Bayer AG
21.3.6.1. Overview & Key financials
21.3.6.2. Disease Indication Portfolio
21.3.6.3. Key Financials
21.3.6.4. Sales Footprint
21.3.6.5. Analysis Commentary
21.3.6.6. Strategy Overview
21.3.6.7. SWOT Analysis
21.3.7. Teva Pharmaceuticals Industries Ltd.
21.3.7.1. Overview & Key financials
21.3.7.2. Disease Indication Portfolio
21.3.7.3. Key Financials
21.3.7.4. Sales Footprint
21.3.7.5. Analysis Commentary
21.3.7.6. Strategy Overview
21.3.7.7. SWOT Analysis
21.3.8. Mylan NV
21.3.8.1. Overview & Key financials
21.3.8.2. Disease Indication Portfolio
21.3.8.3. Key Financials
21.3.8.4. Sales Footprint
21.3.8.5. Analysis Commentary
21.3.8.6. Strategy Overview
21.3.8.7. SWOT Analysis
21.3.9. Glenmark Pharmaceutical Ltd
21.3.9.1. Overview & Key financials
21.3.9.2. Disease Indication Portfolio
21.3.9.3. Key Financials
21.3.9.4. Sales Footprint
21.3.9.5. Analysis Commentary
21.3.9.6. Strategy Overview
21.3.9.7. SWOT Analysis
21.3.10. Taro Pharmaceutical Industries Ltd.
21.3.10.1. Overview & Key financials
21.3.10.2. Disease Indication Portfolio
21.3.10.3. Key Financials
21.3.10.4. Sales Footprint
21.3.10.5. Analysis Commentary
21.3.10.6. Strategy Overview
21.3.10.7. SWOT Analysis
21.3.11. Camber Pharmaceuticals Inc
21.3.11.1. Overview & Key financials
21.3.11.2. Disease Indication Portfolio
21.3.11.3. Key Financials
21.3.11.4. Sales Footprint
21.3.11.5. Analysis Commentary
21.3.11.6. Strategy Overview
21.3.11.7. SWOT Analysis
21.3.12. Breckenridge Pharmaceutical, Inc
21.3.12.1. Overview & Key financials
21.3.12.2. Disease Indication Portfolio
21.3.12.3. Key Financials
21.3.12.4. Sales Footprint
21.3.12.5. Analysis Commentary
21.3.12.6. Strategy Overview
21.3.12.7. SWOT Analysis
21.3.13. Sebela Pharmaceuticals Inc.
21.3.13.1. Overview & Key financials
21.3.13.2. Disease Indication Portfolio
21.3.13.3. Key Financials
21.3.13.4. Sales Footprint
21.3.13.5. Analysis Commentary
21.3.13.6. Strategy Overview
21.3.13.7. SWOT Analysis
21.3.14. Blueberry Therapeutics Ltd
21.3.14.1. Overview & Key financials
21.3.14.2. Disease Indication Portfolio
21.3.14.3. Key Financials
21.3.14.4. Sales Footprint
21.3.14.5. Analysis Commentary
21.3.14.6. Strategy Overview
21.3.14.7. SWOT Analysis
21.3.15. AvKare Inc
21.3.15.1. Overview & Key financials
21.3.15.2. Disease Indication Portfolio
21.3.15.3. Key Financials
21.3.15.4. Sales Footprint
21.3.15.5. Analysis Commentary
21.3.15.6. Strategy Overview
21.3.15.7. SWOT Analysis
21.3.16. Aqua Pharmaceuticals LLC
21.3.16.1. Overview & Key financials
21.3.16.2. Disease Indication Portfolio
21.3.16.3. Key Financials
21.3.16.4. Sales Footprint
21.3.16.5. Analysis Commentary
21.3.16.6. Strategy Overview
21.3.16.7. SWOT Analysis
21.3.17. Exeltis USA, Inc.
21.3.17.1. Overview & Key financials
21.3.17.2. Disease Indication Portfolio
21.3.17.3. Key Financials
21.3.17.4. Sales Footprint
21.3.17.5. Analysis Commentary
21.3.17.6. Strategy Overview
21.3.17.7. SWOT Analysis
21.3.18. CorePharma, L.L.C
21.3.18.1. Overview & Key financials
21.3.18.2. Disease Indication Portfolio
21.3.18.3. Key Financials
21.3.18.4. Sales Footprint
21.3.18.5. Analysis Commentary
21.3.18.6. Strategy Overview
21.3.18.7. SWOT Analysis
21.3.19. McNEIL-PPC, Inc
21.3.19.1. Overview & Key financials
21.3.19.2. Disease Indication Portfolio
21.3.19.3. Key Financials
21.3.19.4. Sales Footprint
21.3.19.5. Analysis Commentary
21.3.19.6. Strategy Overview
21.3.19.7. SWOT Analysis
21.3.20. Aurobindo Pharma Ltd
21.3.20.1. Overview & Key financials
21.3.20.2. Disease Indication Portfolio
21.3.20.3. Key Financials
21.3.20.4. Sales Footprint
21.3.20.5. Analysis Commentary
21.3.20.6. Strategy Overview
21.3.20.7. SWOT Analysis
22. Assumptions and Acronyms Used23. Research Methodolog
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Disease Indication
Table 02: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Route of Administration
Table 03: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Distribution Channel
Table 04: Global Tinea Pedis Treatment Value (US$ Bn) Analysis- and Forecast 2022–2032, by Drug Class
Table 05: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 06: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 07: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 08: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 09: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 10: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 11: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 12: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 13: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 14: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 15: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 16: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 17: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 18: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 19: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 20: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 21: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 22: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 23: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 24: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 25: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 26: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 27: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 28: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 29: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 30: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 31: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 32: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 33: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 34: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Table 35: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 36: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication
Table 37: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration
Table 38: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel
Table 39: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
